{"id":"NCT02829957","sponsor":"Indiana University","briefTitle":"RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding","officialTitle":"Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-09","primaryCompletion":"2020-02-13","completion":"2020-02-13","firstPosted":"2016-07-12","resultsPosted":"2023-05-10","lastUpdate":"2023-11-13"},"enrollment":19,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Venous Thromboembolism","Menstruation"],"interventions":[{"type":"DRUG","name":"Apixaban","otherNames":["Eliquis"]},{"type":"DRUG","name":"Rivaroxaban","otherNames":["Xarelto"]}],"arms":[{"label":"Rivaroxaban","type":"ACTIVE_COMPARATOR"},{"label":"Apixaban","type":"ACTIVE_COMPARATOR"}],"summary":"A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.","primaryOutcome":{"measure":"PBAC Scores","timeFrame":"3 months","effectByArm":[{"arm":"Rivaroxaban","deltaMin":292,"sd":null},{"arm":"Apixaban","deltaMin":146,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["26272306","26970315","26113241","27143861","17532811","23808982","21128814","22449293","23216615"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["PBAC > 100","Crossover to another anticoagulant","Anticoagulant discontinued for more than 48 hours","Worsening DVT","Bleeding that causes unplanned visit to a healthcare provider"]}}